April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Bevacizumab (Avastin®) Monotherapy for Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • J. L. Gottlieb
    Ophthalmol/Visual Science, Univ of Wisconsin-Madison, Madison, Wisconsin
  • A. C. Breunig
    School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin
  • D. L. Johnson
    Ophthalmol/Visual Science, Univ of Wisconsin-Madison, Madison, Wisconsin
  • Footnotes
    Commercial Relationships  J.L. Gottlieb, None; A.C. Breunig, None; D.L. Johnson, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1879. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. L. Gottlieb, A. C. Breunig, D. L. Johnson; Bevacizumab (Avastin®) Monotherapy for Exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1879.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the visual acuity (VA), maximum retinal thickness (MRT) and subretinal fluid thickness as measured by optical coherence tomography (OCT) in patients with exudative age-related macular degeneration (AMD) treated with bevacizumab monotherapy.

Methods: : A retrospective review of the charts and horizontal OCT fast map or cross hair images of 80 eyes of 77 consecutive patients treated by the University of Wisconsin Retina Service with bevacizumab 1.25 mg for neovascular AMD. Inclusion criteria included only patients with choroidal neovascularization due to AMD. Patients had not received prior treatment with any other modality and could only have received treatment with bevacizumab during the course of follow-up. All patients had at least 36 weeks of follow-up. No pre-determined treatment schedule or re-treatment criteria was required. MRT and subretinal fluid thickness was manually measured from the thickest point on the horizontal scan.

Results: : Baseline mean logMar VA was 0.88 and baseline MRT was 376um. LogMar VA at 6 and 12 weeks improved to 0.73 and 0.71, respectively (both p<0.0001) . At 48 weeks the logMar visual acuity measured 0.69 (p<0.001). Mean MRT at baseline was 376 µm, while at 6 and 12 weeks decreased to 251 µm and 265 µm, respectively (both p<0.0001). At 48 weeks the mean MRT measured 285 µm (p<0.0001). Subretinal fluid decreased during the course of follow-up but the change was not statistically significant. At each time point, the number of eyes receiving injections decreased. By 36 weeks the injection rate was 0.38 and by 48 weeks was 0.29. No serious adverse events were identified.

Keywords: age-related macular degeneration • macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.